Cargando…
ASCO 2018: highlights in HER2-positive metastatic breast cancer
At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjug...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280772/ https://www.ncbi.nlm.nih.gov/pubmed/30595754 http://dx.doi.org/10.1007/s12254-018-0441-x |